Biorestorative Therapies Shares Scheduled to Reverse Split on Tuesday, September 8th (NASDAQ:BRTX)

Biorestorative Therapies, Inc. (NASDAQ:BRTX) shares are set to reverse split on the morning of Tuesday, September 8th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 7th.

Biorestorative Therapies Stock Performance

Shares of NASDAQ BRTX opened at $0.14 on Friday. The stock has a market cap of $3.66 million, a price-to-earnings ratio of -0.13 and a beta of 0.83. Biorestorative Therapies has a fifty-two week low of $0.14 and a fifty-two week high of $1.73. The firm’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.28.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Biorestorative Therapies

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC boosted its stake in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the last quarter. Citadel Advisors LLC bought a new stake in Biorestorative Therapies during the third quarter worth $152,000. Finally, DRW Securities LLC purchased a new position in Biorestorative Therapies in the fourth quarter worth $55,000. Institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.